Ipsen Limited
Edit Page
Report
Scan day: 05 February 2014 UTC
18
Virus safety - good
Description: Pharmaceutical company specializing in controlled release peptides and botulinum toxin.
As of Monday 3rd February 2014, all Ipsen products will be distributed via AAH Pharmaceuticals Ltd. Decapeptyl® SR (triptorelin) will be available via AAH and Phoenix/PSUK. Ipsen Limited is the UK subsidiary of Ipsen, a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion in 2012. Ipsen's ambition is to become a global leader in the treatment of targeted debilitating diseases with a development strategy supported by three franchises: neurology, endocrinology and uro-oncology. Moreover, the Group has an active policy of partnerships. Research and Development is focused on innovative patient-driven programmes in the areas of peptides and toxins. In 2012, R&D expenditure totalled more than €250 million, greater than 20% of Group sales. The Group has a total worldwide staff of close to 4,900 employees.
Size: 861 chars
Contact Information
Email: —
Phone&Fax: —
Address: —
Extended: —
WEBSITE Info
| Page title: | Ipsen Limited UK | Home |
| Keywords: | Ipsen Limited,ipsen limited,Ipsen,ipsen,IPSEN,ipsen ltd,Ipsen Ltd,Ipsen UK,ipsen uk,pharmaceutical,pharmaceuticals,Pharmaceutical company |
| Description: | Ipsen Limited is the UK subsidiary of Ipsen, a global biotechnology specialty care Group. Products supplied in the UK include Decapeptyl SR & Salvacyl (triptorelin, LHRH agonist/GnRH analogue), Dysport (clostridium botulinum type a toxin-haemagglutinin complex, botulinum toxin), Increlex (mecasermin - recombinant IGF-1, Insulin-like growth factor), NutropinAq (somatropin, growth hormone) and Somatuline (lanreotide, somatostatin analogue). |
| IP-address: | 213.198.11.133 |